Focused On-demand Library for Glutaminyl-peptide cyclotransferase-like protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9NXS2

UPID:

QPCTL_HUMAN

Alternative names:

Golgi-resident glutaminyl-peptide cyclotransferase; isoQC

Alternative UPACC:

Q9NXS2; Q53HE4; Q96F74

Background:

Glutaminyl-peptide cyclotransferase-like protein, also known as isoQC and Golgi-resident glutaminyl-peptide cyclotransferase, plays a crucial role in the biosynthesis of pyroglutamyl peptides. This process is vital for the proper functioning of various biological systems, as it contributes to the stability and activity of peptides by introducing a pyroglutamyl residue at their N-terminus.

Therapeutic significance:

Understanding the role of Glutaminyl-peptide cyclotransferase-like protein could open doors to potential therapeutic strategies. Its involvement in the biosynthesis of pyroglutamyl peptides suggests a foundational role in cellular processes, which, if modulated, could lead to novel treatments for diseases where peptide stability and function are compromised.